Jessica E Potts1, Cezar A Iliescu2, Juan C Lopez Mattei2, Sara C Martinez3, Lene Holmvang4, Peter Ludman5, Mark A De Belder6, Chun Shing Kwok1,7, Muhammad Rashid1,7, David L Fischman8, Mamas A Mamas1,7. 1. Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, Keele Road, Stoke-on-Trent, UK. 2. Department of Cardiology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA. 3. Division of Cardiology, Providence St. Peter Hospital, Olympia, WA, USA. 4. Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 5. Department of Cardiology, Queen Elizabeth Hospital Birmingham, Birmingham, UK. 6. Department of Cardiology, James Cook University Hospital, Middlesborough, UK. 7. Academic Department of Cardiology, Royal Stoke Hospital, Stoke-on-Trent, UK. 8. Department of Medicine (Cardiology), Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Abstract
AIMS: This study aims to examine the temporal trends and outcomes in patients who undergo percutaneous coronary intervention (PCI) with a previous or current diagnosis of cancer, according to cancer type and the presence of metastases. METHODS AND RESULTS: Individuals undergoing PCI between 2004 and 2014 in the Nationwide Inpatient Sample were included in the study. Multivariable analyses were used to determine the association between cancer diagnosis and in-hospital mortality and complications. 6 571 034 PCI procedures were included and current and previous cancer rates were 1.8% and 5.8%, respectively. Both rates increased over time and the four most common cancers were prostate, breast, colon, and lung cancer. Patients with a current lung cancer had greater in-hospital mortality (odds ratio (OR) 2.81, 95% confidence interval (95% CI) 2.37-3.34) and any in-hospital complication (OR 1.21, 95% CI 1.10-1.36), while current colon cancer was associated with any complication (OR 2.17, 95% CI 1.90-2.48) and bleeding (OR 3.65, 95% CI 3.07-4.35) but not mortality (OR 1.39, 95% CI 0.99-1.95). A current diagnosis of breast was not significantly associated with either in-hospital mortality or any of the complications studied and prostate cancer was only associated with increased risk of bleeding (OR 1.41, 95% CI 1.20-1.65). A historical diagnosis of lung cancer was independently associated with an increased OR of in-hospital mortality (OR 1.65, 95% CI 1.32-2.05). CONCLUSIONS: Cancer among patients receiving PCI is common and the prognostic impact of cancer is specific both for the type of cancer, presence of metastases and whether the diagnosis is historical or current. Treatment of patients with a cancer diagnosis should be individualized and involve a close collaboration between cardiologists and oncologists. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: This study aims to examine the temporal trends and outcomes in patients who undergo percutaneous coronary intervention (PCI) with a previous or current diagnosis of cancer, according to cancer type and the presence of metastases. METHODS AND RESULTS: Individuals undergoing PCI between 2004 and 2014 in the Nationwide Inpatient Sample were included in the study. Multivariable analyses were used to determine the association between cancer diagnosis and in-hospital mortality and complications. 6 571 034 PCI procedures were included and current and previous cancer rates were 1.8% and 5.8%, respectively. Both rates increased over time and the four most common cancers were prostate, breast, colon, and lung cancer. Patients with a current lung cancer had greater in-hospital mortality (odds ratio (OR) 2.81, 95% confidence interval (95% CI) 2.37-3.34) and any in-hospital complication (OR 1.21, 95% CI 1.10-1.36), while current colon cancer was associated with any complication (OR 2.17, 95% CI 1.90-2.48) and bleeding (OR 3.65, 95% CI 3.07-4.35) but not mortality (OR 1.39, 95% CI 0.99-1.95). A current diagnosis of breast was not significantly associated with either in-hospital mortality or any of the complications studied and prostate cancer was only associated with increased risk of bleeding (OR 1.41, 95% CI 1.20-1.65). A historical diagnosis of lung cancer was independently associated with an increased OR of in-hospital mortality (OR 1.65, 95% CI 1.32-2.05). CONCLUSIONS:Cancer among patients receiving PCI is common and the prognostic impact of cancer is specific both for the type of cancer, presence of metastases and whether the diagnosis is historical or current. Treatment of patients with a cancer diagnosis should be individualized and involve a close collaboration between cardiologists and oncologists. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Avirup Guha; Benjamin Buck; Michael Biersmith; Sameer Arora; Vedat Yildiz; Lai Wei; Farrukh Awan; Jennifer Woyach; Juan Lopez-Mattei; Juan Carlos Plana-Gomez; Guilherme H Oliveira; Michael G Fradley; Daniel Addison Journal: Resuscitation Date: 2019-07-13 Impact factor: 5.262
Authors: Michael E Layoun; Eric H Yang; Joerg Herrmann; Cezar A Iliescu; Juan C Lopez-Mattei; Kostas Marmagkiolis; Matthew J Budoff; Maros Ferencik Journal: Curr Treat Options Oncol Date: 2019-05-06
Authors: Mohammed Osman; Mina M Benjamin; Sudarshan Balla; Babikir Kheiri; Christopher Bianco; Partho P Sengupta; Ramesh Daggubati; Midhun Malla; Stephen V Liu; Mamas Mamas; Brijesh Patel Journal: Cardiovasc Revasc Med Date: 2021-04-16
Authors: Bala Pushparaji; Teodora Donisan; Dinu V Balanescu; Nicolas Palaskas; Peter Kim; Juan Lopez-Mattei; Mehmet Cilingiroglu; Saamir A Hassan; Konstantinos Dean Boudoulas; Konstantinos Marmagkiolis; Ludhmila Abrahao Hajjar; Cezar A Iliescu Journal: Curr Oncol Rep Date: 2021-09-27 Impact factor: 5.075
Authors: Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice Journal: Eur Heart J Date: 2019-08-14 Impact factor: 29.983
Authors: Philip Urban; Roxana Mehran; Roisin Colleran; Dominick J Angiolillo; Robert A Byrne; Davide Capodanno; Thomas Cuisset; Donald Cutlip; Pedro Eerdmans; John Eikelboom; Andrew Farb; C Michael Gibson; John Gregson; Michael Haude; Stefan K James; Hyo-Soo Kim; Takeshi Kimura; Akihide Konishi; John Laschinger; Martin B Leon; P F Adrian Magee; Yoshiaki Mitsutake; Darren Mylotte; Stuart Pocock; Matthew J Price; Sunil V Rao; Ernest Spitzer; Norman Stockbridge; Marco Valgimigli; Olivier Varenne; Ute Windhoevel; Robert W Yeh; Mitchell W Krucoff; Marie-Claude Morice Journal: Circulation Date: 2019-05-22 Impact factor: 29.690
Authors: Simone M Mrotzek; Alessia Lena; Sara Hadzibegovic; Ria Ludwig; Fadi Al-Rashid; Amir A Mahabadi; Raluca I Mincu; Lars Michel; Laura Johannsen; Lena Hinrichs; Martin Schuler; Ulrich Keller; Stefan D Anker; Ulf Landmesser; Tienush Rassaf; Markus S Anker; Matthias Totzeck Journal: Clin Res Cardiol Date: 2020-08-02 Impact factor: 5.460